COVID-19 and Cardiovascular Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32200663.
- Also identified by DOI 10.1161/CIRCULATIONAHA.120.046941.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.
Medical subject headings
- Betacoronavirus
- Cardiovascular Diseases
- Coronavirus Infections
- Pandemics
- Peptidyl-Dipeptidase A
- Pneumonia, Viral